Showing results (61-70 of 80) with videos related to
Sort By:
Pageof 8
The New England Journal of Medicine|May 4, 2012
Strategies of radioiodine ablation in patients with low-risk thyroid cancerMartin Schlumberger, Bogdan Catargi, Isabelle Borget, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2014
¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinomaPierre-Yves Salaun, Loïc Campion, Catherine Ansquer, et al.American Journal of Epidemiology|July 3, 2015
Anthropometric Risk Factors for Differentiated Thyroid Cancer in Young Men and Women From Eastern France: A Case-Control StudyConstance Xhaard, Florent de Vathaire, Enora Cléro, et al.American Journal of Epidemiology|October 2, 2014
Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in young women in France: a population-based case-control studyConstance Xhaard, Carole Rubino, Enora Cléro, et al.The Journal of Clinical Endocrinology and Metabolism|November 7, 2018
Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod)Laurence Leenhardt, Sophie Leboulleux, Claire Bournaud, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL TrialIsabelle Borget, Julia Bonastre, Bogdan Catargi, et al.Cancer Epidemiology|January 12, 2018
Dietary habits during the 2 months following the Chernobyl accident and differentiated thyroid cancer risk in a population-based case-control studyConstance Xhaard, Carole Rubino, Vincent Souchard, et al.Thyroid : Official Journal of the American Thyroid Association|August 15, 2018
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid CancerFrancoise Borson-Chazot, Emmanuelle Dantony, Frederic Illouz, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2012
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvementPierre-Yves Salaun, Loïc Campion, Claire Bournaud, et al.European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.Pageof 8